决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up Case.
尽管PCGDTL已知对化疗和放疗反应均较差,但本例表明,局部放疗作为一种低毒性选择,可能在部分老年患者中实现暂时性效果。本报告为PCGDTL非化疗为基础的管理策略的有限文献增添了内容,并强调了在体弱或超高龄患者中个体化治疗策略的重要性。
原发性皮肤γδT细胞淋巴瘤(PCGDTL)是一种罕见且侵袭性强的皮肤T细胞淋巴瘤亚型,常与预后不良和对常规治疗耐药相关。病例介绍:我们报告一例91岁日本男性患者,有2个月面部、躯干和四肢快速生长的疼痛性结节病史。组织病理学显示真皮内非典型淋巴样细胞浸润,CD3和CD5阳性,但细胞毒性标志物如TIA-1和颗粒酶B阴性。流式细胞术证实为TCR-γδ+ T细胞表型。鉴于其高龄,选择了姑息性放疗(8 Gy分4次)。治疗耐受良好,并带来了显著的临床改善,且无不良反应。
INTRODUCTION: Primary cutaneous gamma-delta T-cell lymphoma (PCGDTL) is a rare and aggressive subtype of cutaneous T-cell lymphoma, often associated with poor prognosis and resistance to conventional therapies. CASE PRESENTATION: We present the case of a 91-year-old Japanese man with a 2-month history of rapidly growing, painful nodules on the face, trunk, and extremities. Histopathology showed dermal infiltration by atypical lymphoid cells positive for CD3 and CD5 but negative for cytotoxic markers such as TIA-1 and granzyme B. Flow cytometry confirmed a TCR-γδ+ T-cell phenotype. Given his advanced age, palliative radiotherapy (8 Gy in 4 fractions) was chosen. The treatment was well tolerated and led to dramatic clinical improvement without adverse effects. CONCLUSION: Although PCGDTL is known for its poor response to both chemotherapy and radiotherapy, this case illustrates the potential of localized radiotherapy as a low-toxicity option that may achieve temporary in selected elderly patients. This report contributes to the limited literature on non-chemotherapy-based management strategies for PCGDTL and highlights the importance of individualized treatment approaches in frail or super-aged patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。